North America Infectious Disease Diagnostics Market

North America Infectious Disease Diagnostics Market Size (2024 to 2029)

The size of the infectious diseases diagnostics market in North America is anticipated to grow at a 7.34% CAGR from 2024 to 2029. The North American market is expected to be worth USD 11.26 billion by 2029 from USD 7.90 billion in 2024.

The market for infectious disease diagnostics in the North American region is driven by factors such as the rising prevalence of infectious diseases and increasing spending on R&D to develop better solutions.

Chlamydia, Influenza A and B, Staph, E. Coli, Herpes Simplex 1, Herpes Simplex 2, Shigellosis, Syphilis, Gonorrhea, Norovirus, Salmonella, Tuberculosis, Pneumonia, Hepatitis C, and HIV are a few of the major infectious diseases in the United States. In addition, technological advancements are further favoring the market growth in North America. Shifting the emphasis of healthcare providers from centralized labs to point-of-care testing to provide detailed information about the causative organism and a better understanding of diagnostics in the developed economies is anticipated to boost the market growth during the forecast period.

The various mucus samples, blood, urine, or other bodily fluids were collected for analysis using various diagnostic procedures and instruments. Due to the increasing burden of infectious diseases in North American countries, the demand for testing equipment is expected to see a spike.  Furthermore, increasing adoption of technologically advanced visual diagnostic equipment in healthcare organizations in emerging economies due to increased incidence of various infectious diseases, rising funding from North American governments, increasing focus on improving adequate reimbursement policies in developed economies, high demand for early diagnostic tests by the population are estimated to accelerate the growth rate of the market in the North American region.

However, growing healthcare costs, especially in developed economies, are expected to impact market growth during the forecast period negatively. In addition, a lack of awareness regarding infectious diseases among the population living in underdeveloped localities is further inhibiting the market's growth rate in this region.

This research report on the North American infectious disease diagnostics market has been segmented and sub-segmented into the following categories

North America Infectious Disease Diagnostics Market Analysis By Product

• Instruments
• Reagents
• Services
• Software

North America Infectious Disease Diagnostics Market Analysis By Application

• Hepatitis B
• Hepatitis C
• Human Immunodeficiency Virus (HIV)
• Tuberculosis (TB)
• Chlamydia trachomatis
• Neisseria gonorrhoeae (CT/NG)
• Human papillomavirus (HPV)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• and others (Influenza, Ebola, Typhoid, Malaria, and Dengue)

North America Infectious Disease Diagnostics Market Analysis By Technology

• PCR
• INAAT
• DNA Sequencing
• Hybridization

North America Infectious Disease Diagnostics Market Analysis By End User

• Hospital
• Laboratories

North America Infectious Disease Diagnostics Market Analysis By Country

• The United States
• Canada
• Rest of North America

Regional Analysis

Geographically, North America held the largest share of the global IDD market in 2023. This region is projected to witness a promising growth rate during the forecast years due to the growing adoption of premium diagnostic techniques to sustain the market share of infectious disease diagnostics in a developed region. The infectious disease diagnostics market in North America was the largest in the world. The growing prevalence of infectious diseases is one of the major factors contributing significantly to the domination of the North American region in the global market. The highly developed healthcare system in the United States and Canada, numerous major national clinical laboratories, and simple access to technologically advanced instruments all contribute to the growth of the North American infectious disease diagnostics market. The United States has a well-structured healthcare system because it is a developed economy. This has aided the country's access to the diagnostic tests currently accessible on the market. Diagnostic tests help in early disease detection, which can help prevent the spread of infectious diseases.

The U.S. market had a major share of North America in 2023. The domination of the U.S. in the North American region can be attributed to the increasing number of people suffering from various infectious diseases, leading to high expenditure on the healthcare sector. According to the Centers for Disease Prevention and Control (CDC), an estimated 8916 with tuberculosis, 58371 with salmonella, 34945 with Lyme disease, and 371 with meningococcal were suffered in the U.S. in 2019. In addition, technological advancements are further accelerating the market growth in the U.S. The need to use technologically advanced medical devices in treatment procedures is growing consistently owing to the growing patient awareness regarding the availability of treatment devices. To meet the market demand and acquire a leading market share, the key competitors are adopting strategies such as collaborations, acquisitions, and grant programs such as strategic activities, along with the help of growing regulatory support and investment by the government.

Canada in North America is expected to register promising growth during the forecast period. Due to the country's numerous untapped opportunities, favorable regulatory framework, highly developed healthcare system, improved access to healthcare, and essential industries, Canada is predicted to account for a considerable share of the North American market during the forecast period. In addition, the ease of access to technologically advanced instruments due to more focus on increasing disease surveillance, which can be efficiently through more testing, led to an overall increase in the infectious disease diagnostics market in Canada.

KEY MARKET PLAYERS

Companies playing a dominant role in the North America Infectious Diseases Diagnostics Market profiled in this report are Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, Becton, Dickinson and Company, Cepheid, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.